Jiuyou Capital

Jingxin Microelectronics specializes in the development of communication and information security chips tailored for the new computing sector. The company's product lineup includes chips such as NRS1800, SDI3210, ESW5610, and PRB0400 PCIe to SRIO, among others. These advanced chips and boards are designed to facilitate efficient high-speed data switching, catering to various industries including government, military, finance, energy, transportation, electric power, and telecommunications. By providing these essential components, Jingxin Microelectronics supports the growing demand for secure and reliable data communication solutions.

ReLive Biotechnologies is a biotechnology company focused on developing innovative solutions in orthopedic sports medicine and plastic and reconstructive surgery. The company specializes in cartilage regeneration and repair technologies aimed at treating various cartilage defects, including articular hyaline cartilage, osteochondral, and meniscal injuries. ReLive employs a unique approach that combines multi-source cells with 3D printing bioscaffold materials, facilitating the creation of advanced medical products. These innovations not only enhance treatments for orthopedic conditions but also provide essential supplies for plastic surgeons, underscoring the company's commitment to advancing regenerative medicine and cell therapy.

Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products. It is also committed to promoting the application of second-generation high-throughput sequencing technology in the field of precision medicine. Maijing Gene was established in 2015 and is based in Guangzhou, China.

Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development.

Sinovent Inc. is a biopharmaceutical company established in 2016, with its headquarters in Suzhou, China, and additional offices in Beijing and Boston. The company focuses on developing innovative treatment methods through its advanced biotechnology platform and extensive management experience. Sinovent aims to address global healthcare challenges by combining expertise in science, management, and finance. Currently, it has 12 products in development, primarily targeting oncology, autoimmune diseases, and infectious diseases.

Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases.

Sinovent Inc. is a biopharmaceutical company established in 2016, with its headquarters in Suzhou, China, and additional offices in Beijing and Boston. The company focuses on developing innovative treatment methods through its advanced biotechnology platform and extensive management experience. Sinovent aims to address global healthcare challenges by combining expertise in science, management, and finance. Currently, it has 12 products in development, primarily targeting oncology, autoimmune diseases, and infectious diseases.

SmartNuclide is focused on the discovery, manufacture, and marketing of nuclear medicine pharmaceuticals, specifically in the fields of diagnostics and therapeutics for cancer treatment. The company engages in research and development of radiopharmaceutical medications, including recombinant proteins and imaging agents. By concentrating on molecular nuclear oncology, SmartNuclide aims to provide innovative biological drug products that enhance the reliability and effectiveness of cancer therapies. Through its development pathways, the company seeks to contribute significantly to the biotechnology industry by offering advanced solutions for diagnosing and treating cancer.

Linpowave specializes in the development and manufacturing of millimeter-wave radar detection systems tailored for automobiles, drones, robots, and security applications. Their technology encompasses advanced radar sensors and systems that enhance safety and efficiency across various sectors. The company's products facilitate traffic monitoring, road condition detection, and are employed in diverse applications such as UAV obstacle avoidance, ground imitation flight, robot simultaneous localization and mapping (SLAM), intelligent driving, and intelligent transportation. With a focus on delivering high-quality sensor systems, Linpowave aims to support enterprises in optimizing their operational capabilities.

Denovo Biopharma is a privately held biotechnology company focused on personalizing drug development through innovative biomarker discovery. The company has developed a unique platform and algorithm that enables the retrospective identification of genomic biomarkers using archived clinical samples. This technology is particularly beneficial for late-stage clinical drugs that have previously shown unsatisfactory efficacy, allowing for the identification of biomarkers that correlate with patient responsiveness to specific drug candidates. By leveraging this approach, Denovo Biopharma assists biotech and pharmaceutical companies in designing targeted clinical trials aimed at enhancing drug efficacy and minimizing adverse effects. The platform's applications extend across various therapeutic areas, including oncology, metabolic disorders, cardiology, immunology, and neurology.

Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meet cost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

OncXerna Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for cancer patients by utilizing an RNA-based biomarker platform. The company aims to improve patient outcomes by prospectively identifying individuals based on the unique RNA biology of their tumor microenvironments. This innovative approach enables OncXerna to match patients with targeted oncology therapies that correspond to their specific tumor characteristics. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, OncXerna was formerly known as Oncologie, Inc. and changed its name in September 2020 to reflect its commitment to advancing next-generation precision medicine for a broader range of cancer patients.

Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meet cost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system.

SenseFuture is a laser radar technology developer, focusing on providing laser radar and machine vision fusion solutions for robots and unmanned vehicles. Based on the detection performance of photoelectric algorithms, it can meet the needs of unmanned environment perception. Beijing Weisen Technology Co., Ltd., which is a robot and unmanned sensory, provides fusion sensing solutions such as laser radar and vision. The company was registered in May 2018. Prior to this, relying on the talent team and environmental platform of Peking University,they have accumulated 2 years of research results in the field of laser radar.

Beijing Tianyishangjia New Material Corp., Ltd. specializes in the research, development, production, and marketing of advanced braking systems for various modes of transportation, including high-speed trains, urban rail transit vehicles, and locomotives. Founded in 2009 and based in Beijing, the company offers a diverse range of products, such as sintered brake pads, brake blocks, and organic brake components. In addition to its core offerings, Tianyishangjia New Material focuses on innovative research in carbon-based composite materials and resin-based carbon fiber composites, enhancing its product line and industrial applications in large transportation and new energy sectors. The company is committed to advancing material technologies and precision manufacturing processes, contributing to the safety and efficiency of modern transit solutions.